WO2007066737A1 - 核酸の複製の方法及び新規人工塩基対 - Google Patents
核酸の複製の方法及び新規人工塩基対 Download PDFInfo
- Publication number
- WO2007066737A1 WO2007066737A1 PCT/JP2006/324484 JP2006324484W WO2007066737A1 WO 2007066737 A1 WO2007066737 A1 WO 2007066737A1 JP 2006324484 W JP2006324484 W JP 2006324484W WO 2007066737 A1 WO2007066737 A1 WO 2007066737A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- group
- acid
- added
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/044—Pyrrole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Definitions
- Et al. Have developed hydrogen isotopes (soG soC) and xanthone anolines that are different from natural tans. These were applied to PC containing pieces (89), and (). However, it requires a relatively modest and / or cumbersome method. In addition to these subjects, it is not recognized by soC and the anopines, 2 anopidines, and 7-pom- erase. Therefore, these are limited.
- soC soC
- 2 anopidines 2 anopidines
- 7-pom- erase 7-pom- erase. Therefore, these are limited.
- oo et al. Synthesized a base that has a form similar to the natural group, but lacks the ability to form a bond at the base (2). These sex bases were selectively recognized by pomerase, suggesting that, in replication, the geometrical complementarity of hydrogen rather than hydrogen bonds is important. Recently, it was developed by a series of sex bases, oesbe et al.
- 001 4 quaternary pomerase consists of 35 quaternary pigments, 4 pomerases and conventional pomerases (eg e ococc soas e pomerase) The method according to item 3 without aspect selected from the group.
- the deoxyribooctanoic acid to be 001 4 5 has a group of:
- the deoxyribooctanoic acid which is 001 56, has a natural group, and is described in item 4 of the non-embodiment.
- the deoxybodic pentanoic acid that is 016 7 is
- deoxycarbonyl pentacarboxylic acid having a group represented by: 5.
- Deoxybodic pentanoic acid which is 00198 is the following
- the deoxycarbonyl pentacarboxylic acid having a group represented by: 5.
- Is hydrogen is a substituted or substituted C C achi, is a substituted
- a nucleic acid that has a group represented by and forms a base that has a group represented by and forms a base.
- the base of 003 1 4 is
- Shigeo wheat which is said to have been written in the breath by Hata Ihata I3, which is made into a cedar from the groo that is composed of Le Ge.
- Aspect 3 selected from the group consisting of
- Is a photogroup An acid containing a quorum having a group represented by is transcribed as a type, reverse transcription replication is performed, and a quo having the above group is incorporated at a position of the quo having the group 2 above.
- the above-mentioned manufacturing method comprising:
- the acid containing a quorum having a group represented by is transcribed as a mold, and reverse transcription replication is performed by transferring the above-mentioned group 2 to the position of the quo having a group.
- the above-mentioned manufacturing method comprising:
- the antisense is a body or an apta.
- Quadrant having a group represented by.
- Quadrant having a group represented by.
- the quadrant 5 which is 3 or a C 2 C achi group.
- 006 007 a is 5 s C (P 75) OCT and
- Ply, 55, and • 35 quad pentanoic acid were used for C.
- the data were averaged over a set of 3 and 8 data sets.
- the replication property is further improved.
- the utilization of modified pentanoic acid reduces the loading rate compared to that of the non-converted one, the artificially incorporated reaction can be practically used by the selection. Well proceed.
- the method for the hydroxyl group of the acid at the v-position of deoxyribooctanoic acid is not particularly limited, and the following method can be used.
- 13 (5) (6) herein discloses the corresponding quads in the case of substituted ano groups.
- 47 also discloses the laws of Adequo.
- methiano, methiano, mecapto, o, and ano can be synthesized by a method known to those skilled in the art.
- Cyclic pomerases consist of groups of 35, which are pigments, 4 pomerases and conventional pomerases (e.g. e ococc soas e pomerase). To be selected.
- the group of groups in the present invention is not particularly limited, and for example, deoxybox having the following groups is used.
- the group 0104 and the deviation of 2 also show excellent selection and efficiency in replication even when used as the deviation of the template. In addition, it shows excellent selection and efficiency for transcription.
- the oxo-octanoic acid which is 0,06 or, may have a natural group.
- Deokinokudo no Aden ( ), Guan (G), and ton (C) tin () are known.
- deoxycarbonyl pentanoic acid, in which the hydroxyl group of the acid at the v-position is substituted, is effectively used as well.
- the deoxyquinodecanoic acid of 0108 may have a group of or a natural group. of ,
- the method for producing the nucleic acid is as described above.
- the deoxy quinodecanoic acid of 0109 Akira can be used as in the above-mentioned production process of Akira.
- a nucleic acid having a group represented by [0117] means that a nucleobase and a sugar group are bound by a bond. It should be noted that the acid-base is intended to include Ade, guar, ton, tin, ura, and the conductors of these groups. The type of conductor is not particularly limited, and specific examples thereof include the group represented by the above and the group represented by 2. Quo means that the amount of the quads mentioned above is not available. More preferred is one, or three. Quad or Quad, 2 Deokibo, or Gege has 2nd place 2
- the hydroxyl group of the acid at the V-position is substituted with a group selected from the group consisting of nitrogen, ano, methano, methano, mecapto group and o. Hope that. Minutes, quads, quads, quads, or the composition found in these conductors. Quo whose minutes are is minutes of, and Deokiki quo, which is minutes, is minutes of.
- the thia group is a substituent, or the 4- and / or 5-position is selected from the group consisting of a methyl group, an aryl group, a to group and a chi group. It may be replaced by more groups.
- 0120 also includes a case where s is a hydrogen atom or a case where it is a hydrogen atom or an amino group.
- s is a case where is an ano group
- s is a case of hydrogen, and s is described separately according to the following.
- 0121 can be either or. Of, for example, s.
- For C for example, express s.
- s includes s and the like.
- s and s may be collectively referred to as s.
- 0 22 is not fixed, but preferably,
- 0 (124) is more preferable than 0124.
- the group of Ming, the quad containing it, and the quo can be synthesized by the method of. Physically, for example, 3 Is 2 ano 3 to 4 quinine (compound of 1) (4) to 7 (2) 3 4 5 b 3 ii (s) quad 5 acid and 5 adon (1 or The method for synthesizing 4) is disclosed. In addition, Implementation 11 is 7 (2) 3
- the practice discloses a method for synthesizing quad 5 acids of 4 (2 2 3 b gin (s) 4 (2) 2 3 b gin ().
- Adonates can also be synthesized using methods similar to those physically disclosed in this specification and / or known to those skilled in the art.
- 0131 Ochin also called, is a member of the Vitan group. It is known that biotin binds to Avidi specific, which is a protein contained in, to form a complex. Therefore, a quad having otine as a substituent specifically binds to an avidin protein. For this reason, it can bind when avid is bound, including quads that have biotin bound, so that nucleic acids can be immobilized and separated, and nucleic acids that bind to specific molecules (such as If it becomes, for example,
- the photomolecule is capable of utilizing the photomolecule of, but preferably 5
- the large wavelength of is, and the fluorescence large wavelength of is. Also,
- the absorption wavelength of R is 578 and that of fluorescence is 578.
- the large wavelength of S is 8 and the large wavelength of fluorescence is 8.
- the large wavelength of X is, and the large wavelength of fluorescence is.
- the large wavelength of is, and the large wavelength of fluorescence is.
- the large wavelength of 5 X is 5 and the large wavelength of fluorescence is 5.
- the 6 X large wavelength is, the fluorescence large wavelength is
- a quad or a quad having a group of formula 2 having a substituted photomolecule is capable of producing a group depending on the type of fluorescent molecule.
- the photomolecule may be directly bonded through the ano group or may be bonded through the anchor.
- the type of anchor is not particularly limited, and those skilled in the art can use it. Although not limited to the above, preferably 1 and 11 below.
- 0139 R is a photogroup.
- 2 is a group, it is referred to herein as Pa or Pa depending on the context.
- P is a group, it is referred to herein as P or P, depending on the context.
- Pa, Pa, P, P, etc. may be collectively referred to as Pa.
- 040 is not fixed, but preferably 2 or less
- 6 is Pa or Pa conductor
- 72 is P or
- Pa can be introduced from its source, for example, picaboride, for example, dc 3 29 8 ec 8 757 4.
- the Pa conductor can be basically synthesized by conducting from Pa.
- a conductor that introduces a poppy in the 4th position of Pa is described in oo ed ee ⁇ 3 ⁇ 45 5 45 8 (2 3) (28).
- p2carboaldehyde (j) p2carboaldehyde (7) was synthesized.
- a nucleic acid having a group having a group of 0, a group having a group of 2 and a group having a group of 2 is formed.
- more quanta means a nucleic acid molecule bound in the 5 3 direction. Including one, two, or. , R, or. Also, is reverse-transcribed as a mold. Is also included.
- a quo having a group of formula 2 is a quo having a group of formula 2 Exist on two nuclei that form two by. Or, Quo may exist on the same book. In this case, the base may form a single structure.
- Quo having a group of 0150 and a group having a group of 2 can be incorporated into the nucleus by replication, transcription, reverse transcription reaction, or the like. Alternatively, it may be incorporated by or by chemical synthesis, as well as a quad or quad having a natural group.
- a base is formed in the process of transcription, or reverse transcription of nucleic acid.
- a quo having a group of is a part of, and a quo having a group of 2 is a part of, or vice versa.
- a quo having a group may be a part, and a quo having a group 2 may be a part.
- the outline of the stem of 0153 is shown in Fig. C.
- the effects on the production of the Ming stem are shown, for example, in 2b e, 3b and 82.
- Is hydrogen is a substituted or substituted C C achi, is a substituted
- 3 is a group selected from a substituted C 2 C3 group or a substituted or substituted C C3 group, and
- An acid containing a quorum having a group represented by is transcribed as a type, reverse transcription replication, and a quo having the above group is incorporated at a position of the quo having the above group 2.
- 0159 is also the following 2
- the acid containing a quorum having a group represented by is transcribed as a type, and the reverse transcription replication is performed, and the quo having the group 2 is incorporated at a position of the quo having the group
- 0165 is further intended to provide an acid prepared by the method described above or containing a quo having a group of formula 2.
- Nucleic acid into which the bright quan is incorporated is used as an antisense or as a vaccine or tag.
- Antisense is or that suppresses the appearance of a particular gene. It was named as a complement to the partial sequence of the target gene sequence (sense). It is used as a method to adjust the gene expression.
- Antisense or embedded with Mingo Quo contains a group Create something with different complementarity to the target compared to using only natural groups. Is a component of. Apta, a nucleic acid obtained by the o-section method and having the function of binding to a certain element of a tank
- the quasi nucleic acid (or) (eg, synthetic) of the present invention may be a part of a tank or a peptide. It is used as a light gene fragment or light source.
- natural genes with more additions of the quanta of the present invention, or combinations of these are also included.
- nucleic acid into which a quat having an explicit group is incorporated is incorporated.
- Is a phenomenon in which two (ds) are decomposed and the expression of the gene is suppressed.
- a typical example of Wataru is ds.
- Isa () belonging to 111a sets up 2 23 s s o e fe R s with about 2 ongs on the 3rd end. s is incorporated into s white matter called SC and decomposes the sequence R. It has been shown to be a phenomenon that is conserved in a wide range of species such as, (human, mouse, etc.), nematode, plant, leopard, and so on. Nucleic acids that incorporate a quat having an explicit group can be used as s in interactions or as part of undergoing degradation.
- a quad pentanoic acid having a group represented by is provided.
- 0172 is the following 2
- Is hydrogen is a substituted or substituted C C achi, is a substituted
- a quad pentanoic acid having a group represented by is provided.
- the R ano group includes a meth-, iso-, and benzoi-substituted ano group.
- 0 80 is the same as
- Example 8 was synthesized in Example 1 as a substance contained in 0181.
- Is hydrogen is a substituted or substituted C C achi, is a substituted
- 0186 R is the same as 2.
- 0187 R is the same as 2.
- 0189 a a is a system that enables singularity and copying. a represents s Pa and.
- b a is a system that allows singularity and copying.
- b shows the structures of 5 '(dP) and 5'adonic acid as for PC and ply length.
- c a is a system that allows singularity and copying. c indicates the PC width, the ply length, the ken, and the stem that functions at 7.
- 2a 2a e for stem quats and plies with s Pa. 2a is a row of plies for the entrance test.
- 2b shows the ratio of (d P) to the group by e o.
- 2c shows the ratio of (d P, Pa, G, C, and modified d P, s and) to the group by e o.
- 2d 2a e for stem quats and plies with s Pa shows the result of applying 5 between eo and 5 with dPa P and a form containing dPa in the absence of ds P.
- 2e is a type, including Pa, plus a series (ds P and P) by eo or eo "
- 3a 3a is the width and the PC width of the piece containing s Pa. 3a shows the experiment. (5e) was prepared by ply length using synthetically synthesized (9e and 8e) containing s and Pa.
- 3b 3a is the width and the width of the piece containing s Pa. 3b shows the first (cycling) and 5 and a post-cycling sample of the PCR product. Cycle your PC at (94C, O / 545C, O / 565C, 4) x 4 x
- Co containing only groups is a cyclized P C at (94. C, O. 5 45. C, O. 5 72. C,).
- 3c 3a is the width and the PC width of the piece containing s Pa. 3c shows the result of PC determination according to the procedure described for 3ab. (D) and (e) with stem (d) and (e) after dsP P (cf) or non-existent of (c) and PC's pre-PC after (s) PC or after natural-only Syc PC () Kenting in ().
- 0193c is the result of the dPa P of PC (cycl).
- the fourth group is a group corresponding to the s position of the template, and Pa is incorporated at this position in the reaction. Therefore, only at this position, the gap between G and C disappears.
- 3d 3a is the cage and PC width of the piece containing s Pa. 3c follows the procedure described for 3a b. The result of PC setting is shown. 3d is the result of the dPa P after the cycle PC.
- the fourth group is a group corresponding to the s position of the template, and Pa is incorporated at this position in the reaction. Therefore, only at this position, the gap between G and C disappears.
- 3e 3a is the width and the width of the piece containing s Pa.
- 3c shows the result of PC determination according to the procedure described for 3ab.
- 3e is the result of the dPa P after the cycle PC.
- the fourth group is a group corresponding to the s position of the template, and Pa is incorporated at this position in the reaction. Therefore, only this place, the gap between G and C disappears.
- 3 3a is the width and width of the PC containing s Pa.
- 3c shows the result of PC determination according to the procedure described for 3ab.
- 3f is the result of the dPa P quantification after PC (cycling) under the condition that s Pa does not exist in nature.
- the P in the template, which corresponds to the fourth group, is completely replaced (the fourth group).
- 39 3a is the width and the PC width of the piece containing s Pa.
- 3c shows the result of PC determination according to the procedure described for 3ab.
- 3 is the result of the ken in the presence of dPa P of PC (cycl).
- the fourth group is a group corresponding to the s position of the template, but since there is no group forming the s singularity, this drop is almost eliminated.
- 3h 3a is the width and the PC width of the piece containing s Pa.
- 3c shows the result of PC determination according to the procedure described for 3ab.
- Figure 3 is the result of the Kening in the presence of dPa P after the Cyclo PC.
- the fourth group is a group corresponding to the s position of the template, but since there is no group forming the s singularity, this drop is almost eliminated. However, the base Obstacles are also observed. The size of this overlook was naturally increased by the increase in the number of PC cycles.
- 3 3a is the width and width of the PC containing s Pa.
- 3c shows the result of PC determination according to the procedure described for 3ab.
- Figure 3 is the result of the Kening in the presence of dPa P after the Cyclo PC.
- the fourth group is a group corresponding to the s position of the template, but since there is no group forming the s singularity, this drop is almost eliminated. However, uptake of the base is also observed. The size of this overlook was naturally large due to the increase in the number of PC cycles.
- 4a 4 is at 7 mediated by s Pa.
- 4a 4b is a skit of the experiment.
- 4b 4 is at 7 mediated by s Pa. 4a 4b is a skit of the experiment.
- 4c 4 is at 7 mediated by s Pa. 4c indicates a target using Pa P, Pa P or S P () or a natural P () (s Pa Pa, or C) in the absence thereof.
- 4d 4 is at 7 mediated by s Pa.
- 4d 4 e shows the result of 2 C analysis of quaternic acid obtained from the transcript (7 e).
- 4e 4 is at 7 mediated by s Pa.
- 4d 4 e shows the result of 2 C analysis of quaternic acid obtained from the transcript (7 e).
- 5a 5 is for child 7 containing anti.
- 5a is a natural product of Pa P (3) or s P (2) Use (4 and co 4) of P (2 or 3)
- 5c 5 is for child 7 containing anti.
- 5b 5c are the
- 5d 5 is for child 7 containing anti.
- 5d is in the large intestine stem (S Roc e)
- 6 6 shows the strip rows for PC, Ken and test.
- P0 is the number of plies
- 1 is the count of hands that correspond to u products
- o is the counsel of the end of the world. The determined values are shown in the table below.
- 13 3 shows the results of die-tanking of two PCs using ply.
- 15 5 shows the result of die-tanking of 4 PCs using ply.
- 16 6 shows the result of die tokening of 5 PCs using ply.
- 17 7 shows the result of die tokening of 6 PCs using ply.
- Numeral 199 shows the result of die tokening of eight PCs using ply.
- 21 2 shows the scan of anti-containing anions in the stem from the large intestine
- 22 22 is a quad of 7 (2) 3 4 S b Shows skis for conductors. Drugs and (a) Cubis (toin) radium, 2 (tosta) on, (b) Radium, boron, Tanno, Chi (c) (d) a 2 Deoki 3 5 Tooi pentora Ku
- 23 23 is a quad conductor of 4 pibode hydrate, 4 pi pibobode hydrate, 6 ano 9 (2 deoxy
- 24a 24 is 7 (2) 3 4 5 b gin (s) Shows the spec of odds. 24a is the (z OSO d) spectrum of 6.
- 24b 24 shows the spectrum of quads of 7 (2) 3 4,5 b gin (s). 24b is a (27 z OSO d) spect (7 9) of 6.
- 24c 24 shows the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24c is a spect (OSO d) of 6.
- 24d 24 shows the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24d is O Spect (OSO d).
- 24e 24 shows the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24e is the C (75 z S d) spectrum of 6.
- 24 24 shows the spectrum of quads of 7 (2) 3 4,5 b gin (s). 24f is a 2 COS spectrum of 6.
- 249 24 shows the spectrum of quads of 7 (2) 3 4,5 b gin (s). 24 is a 2 OS spectrum of 6.
- 24h 24 has a spectrum of 7 (2) 3 4,5 b gin (s) quads. 24 is a 6 2 SQC spectrum.
- 24 24 indicates the spectrum of the quad of 7 (2) 3 445 b gin (s). 24 is a 2 C spectrum of 6.
- 24 24 shows the spectrum of the quad of 7 (2 3 4 5 b gin (s. 24 shows the 2 C spectrum of 6 ( ).
- 24 24 shows the spectrum of the quad of 7 (2) 3 4 S b gin (5). 241 is a 2 COS spectrum.
- 24m 24 shows the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24 is the 2 OS spectrum of.
- 24n 24 indicates the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24 is the 2 SC spectrum.
- 24 24 shows the spectrum of quads of 7 (2) 3 4,5 b gin (s). 24 is a 2 C spectrum.
- 24p 24 shows the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24 is the 2 C spectrum ().
- 25a 25 indicates the spectrum of quads of Phi Phi 2 borahdede 4 pipi 2 25a is the (3 z S d) spectrum of 7.
- 25b 25 is Phibobodehi 4 Phi Phi 2
- 25c 25 indicates the spectrum of the quads of Phi Phi 2 borahdede 4 Phi Phi 2 borah. 25c is a 2 COS spect of 7. 25d 25 indicates the spectrum of the quads of Phi Phi 2 Cabo Dehide 4 Phi Phi 2 Cabo Dehide. 25d is a 7 2 SQC spectrum.
- 25e 25 indicates the R-spectrum of the quad of Phi Phi 2 bordehide 4 pi Phi 2 cmergedehi. 25e, 7 of 2
- 259 25 shows the R-spectrum of the quads of Phi Phi 2 bordehide 4 pi Phi 2 cabohide. 25 is the (3 z S d) spectrum of 8.
- 25h 25 is Pabo 2 Phi Phi 2 Phi Phi 2
- 25 25 indicates the R-spectrum of the quads of Phi Phi 2 Cabo Dehydr 4 Phi Phi 2 Cabo Dehydr. 25 is a 2 COS spect of compound 8.
- 25 25 indicates the R-spectrum of the quads of Phi Phi 2 Cabo Dehydr 4 Phi Phi 2 Cabo Dehydr. 25 is the 2 O S spectrum of compound 8.
- 25k 25 indicates the R-spectrum of the quad of Phi Phi 2 bordehydr 4 pi Phi 2 bordehyde. 25 is a 2 SQC spectrum of 8.
- 25 25 indicates the R-spectrum of the quads of Phi Phi 2 Cabo Dehydr 4 Phi Phi 2 Cabo Dehydr.
- the 251 is the 2 C spectrum of compound 8.
- 25m 25 is Phi Phi 2 Shows the spect's spect spectrum. 25 is the O-spect (OSO d) of 7.
- 25n 25 indicates the R-spectrum of the quad of Phi 2 Cabo Dehydr 4 Puphi 2 Cabo Dehydr. 25 is the O-spect (OSO d) of 8.
- 27 27 is the S-spectrum of deoquinic acid.
- 28a 28a is the (27 z O) spectrum of deoquine 5 Y adonate.
- 28b 28b is the (g z O) spectrum of deoquine 5 adonate.
- 29a 29a is 7 (2) 3 (2 deoki j
- 29b 29b is 7 (2) 3 (2 deoki j
- 30b 3b shows the (27 z O) spectrum of (j) pi 2 carbode 5 (9).
- 30c 3c is the (27 z O spectrum of 4 Puphi (j) 2 cabohide 5 (2. 31a 3 a is 7 (2) 3 (j) 3. 31
- 31b 3 b shows the P (g z O) spectrum of (j) p 2 carbode 5 (9). 31c 3 c is 4 pp (j) pi 2
- 33 33 indicates a skid for a quad conductor of 7 (2) 34 S b. Medicine and (a)
- 34 34 shows the skid of a 2-topi () quad conductor. Medicine and (a) a 2 Deoki 3 5 Tooi
- 35 35 is 4 (2) b.
- 36 36 is (j) 4 (e.
- 38a 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24).
- 38a is the (3 z SO d6) spectrum of 24.
- 38b 38 shows the spectrum of (j) 4 (quad) puppies 2 cannodes (24.
- 38b shows 2 13
- 38c 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24). 38c is a 24 COS spectacle of 24.
- 38d 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24). 38d has 24 2 OS specs.
- 38e 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24). 38e is a 24 2 QC spectrum.
- 38 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24). 38f is the 2 C spectrum of 24.
- 389 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24). 38 is the 2 C-spectrum () of 24.
- Phi 2 Kadehid 5 Tosto (28) is shown by ionic color.
- 43a 43 indicates the spectrum of (j) 4 (Ochinaduppi) Pi 2 cadhide 5 toss (28). 43a has 28 (3 z O) spects
- 43b 43 indicates the spectrum of (j) 4 (Ochinaduppi) pi2cadehide5host (28). 43b is a 28 2 COS spect.
- 44a 44a shows the formation of biotinylated Pa P (o Pa P 28).
- 44b 44b shows the transcription and analysis of R-biotin by 7 using s Pa.
- 44c 44c is the true result of the biotin experiment of R-child with 7 using s Pa. 4 is .
- the model obtained by the computer, 52 is the result when using the PC width type.
- 44d 44d is a true indicator of the effect of biotin analysis.
- the biotin-streptavidin complex was separated from the 7-quadruplicate gel, and the () of the complex was determined from time to time.
- 44e 44e is the result of the analysis of 52 e containing o Pa or in the 59th position 32
- 45 45 indicates a skid of a 2-topic 4-quad conductor.
- 48 48 shows the entry scheme in (55 e), and the result, of P bound with an element, which is produced by using cement.
- 49 49 shows the entry scheme and its consequences in the (7 e) of Pa bound to a fluorophore using a 7 R polymerase.
- the conductor was manufactured in 8 columns (Scoa RPP 25 X4 6coecooes).
- 7 (2) 3 4 5 b described in 22. Physically, 7 (2) 3 445 b gin (4) is 2 ano 3 to 4 gin (compound (
- the 2022 quad pentanoic acid was synthesized according to the method disclosed in the prior art document (4345). 5 For adonic acid, the standard method (43) was modified. 9 2 marked quads. 2 4 3 2 It was turned on by Benzos 4. The quadruple conductors are
- the dried quad (o, compound 9 or 3) was dried with. It was dissolved in gin (OOu) xanthane (34. To this was added 2 4 3 2 benzoso 4 ondioxane (O 2, .o), followed by .5 bis (tothian).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006800525963A CN101365791B (zh) | 2005-12-09 | 2006-12-07 | 核酸的复制方法及新型人工碱基对 |
US12/096,517 US8030478B2 (en) | 2005-12-09 | 2006-12-07 | Method for nucleic acid replication and novel artificial base pairs |
KR1020087016493A KR101404374B1 (ko) | 2005-12-09 | 2006-12-07 | 핵산의 복제방법 및 신규한 인공 염기쌍 |
AU2006323745A AU2006323745B2 (en) | 2005-12-09 | 2006-12-07 | Method for replicating nucleic acids and novel unnatural base pairs |
JP2007549184A JP5146957B2 (ja) | 2005-12-09 | 2006-12-07 | 核酸の複製の方法及び新規人工塩基対 |
CA002642657A CA2642657A1 (en) | 2005-12-09 | 2006-12-07 | Method for replicating nucleic acids and novel unnatural base pairs |
EP06834239A EP1970445B1 (en) | 2005-12-09 | 2006-12-07 | Method for nucleic acid replication and novel artificial base pairs |
HK09101422.7A HK1121491A1 (en) | 2005-12-09 | 2009-02-16 | Method for nucleic acid replication and novel artificial base pairs |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005356883 | 2005-12-09 | ||
JP2005-356883 | 2005-12-09 | ||
JP2006-189806 | 2006-07-10 | ||
JP2006189806 | 2006-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007066737A1 true WO2007066737A1 (ja) | 2007-06-14 |
Family
ID=38122882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/324484 WO2007066737A1 (ja) | 2005-12-09 | 2006-12-07 | 核酸の複製の方法及び新規人工塩基対 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8030478B2 (ja) |
EP (1) | EP1970445B1 (ja) |
JP (1) | JP5146957B2 (ja) |
KR (1) | KR101404374B1 (ja) |
CN (1) | CN101365791B (ja) |
AU (1) | AU2006323745B2 (ja) |
CA (1) | CA2642657A1 (ja) |
HK (1) | HK1121491A1 (ja) |
WO (1) | WO2007066737A1 (ja) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009099073A1 (ja) * | 2008-02-07 | 2009-08-13 | The University Of Tokyo | 非天然塩基を含む改変tRNA及びその用途 |
WO2009123216A1 (ja) | 2008-03-31 | 2009-10-08 | 独立行政法人理化学研究所 | 高選択・高効率でpcr増幅が可能な新規dna |
WO2011043385A1 (ja) | 2009-10-06 | 2011-04-14 | 独立行政法人理化学研究所 | 特異な塩基対を形成する人工塩基対 |
WO2013073602A1 (ja) * | 2011-11-18 | 2013-05-23 | 独立行政法人理化学研究所 | 標的タンパク質に結合する核酸断片 |
US10513706B2 (en) | 2014-04-09 | 2019-12-24 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
US10610571B2 (en) | 2017-08-03 | 2020-04-07 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
US10626138B2 (en) | 2013-08-08 | 2020-04-21 | The Scripps Research Institute National Institutes Of Health (Nih), U.S. Dept Of Health And Human Services (Dhhs) | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
US10696720B2 (en) | 2016-06-24 | 2020-06-30 | The Scripps Research Institute | Nucleoside triphosphate transporter and uses thereof |
JP2021518127A (ja) * | 2018-03-21 | 2021-08-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 高熱安定性を持つ修飾ヌクレオシドホスフェート |
US11077195B2 (en) | 2019-02-06 | 2021-08-03 | Synthorx, Inc. | IL-2 conjugates and methods of use thereof |
WO2022131350A1 (ja) * | 2020-12-18 | 2022-06-23 | タグシクス・バイオ株式会社 | Dnaアプタマーのスクリーニングに使用可能な新規人工塩基を有するデオキシリボヌクレオシド、デオキシリボヌクレオチド、およびこれを含有する核酸 |
US11761007B2 (en) | 2015-12-18 | 2023-09-19 | The Scripps Research Institute | Production of unnatural nucleotides using a CRISPR/Cas9 system |
US11834689B2 (en) | 2017-07-11 | 2023-12-05 | The Scripps Research Institute | Incorporation of unnatural nucleotides and methods thereof |
US11879145B2 (en) | 2019-06-14 | 2024-01-23 | The Scripps Research Institute | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms |
US11919934B2 (en) | 2018-02-26 | 2024-03-05 | Synthorx, Inc. | IL-15 conjugates and uses thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5649018B2 (ja) | 2005-08-04 | 2015-01-07 | タグシクス・バイオ株式会社 | 新規人工塩基対及びその利用 |
EP3369820B1 (en) * | 2015-10-30 | 2021-12-08 | TAGCyx Biotechnologies Inc. | Dna aptamer capable of bonding to vwf |
WO2017205336A1 (en) * | 2016-05-23 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Nucleotide derivatives and methods of use thereof |
JP2022519020A (ja) * | 2019-01-31 | 2022-03-18 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 非天然塩基対を用いて核酸を配列決定する方法 |
CN111214484B (zh) * | 2020-01-21 | 2021-04-06 | 北京工商大学 | 一种共轭聚合物和聚集诱导发光小分子共掺的纳米粒子及其制备方法和应用 |
KR20220125170A (ko) | 2021-03-04 | 2022-09-14 | 전북대학교산학협력단 | 인공 염기 화합물, 이를 포함하는 핵산 및 이의 용도, 및 핵산 제조 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200604211T1 (tr) * | 1999-02-12 | 2007-02-21 | Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited | Yeni nükleosid ve oligonükleotid analoglarıYeni nükleosid ve oligonükleotid analogları |
JP3893057B2 (ja) | 1999-07-15 | 2007-03-14 | 独立行政法人科学技術振興機構 | 新規な核酸塩基対 |
WO2004007713A1 (ja) | 2002-07-17 | 2004-01-22 | Riken | 新規な非天然型塩基を有するヌクレオシド又はヌクレオチド及びその利用 |
US20110087015A1 (en) | 2003-09-10 | 2011-04-14 | Riken | Nucleoside and nucleotide having an unnatural base and use thereof |
JP5649018B2 (ja) | 2005-08-04 | 2015-01-07 | タグシクス・バイオ株式会社 | 新規人工塩基対及びその利用 |
-
2006
- 2006-12-07 WO PCT/JP2006/324484 patent/WO2007066737A1/ja active Application Filing
- 2006-12-07 KR KR1020087016493A patent/KR101404374B1/ko active IP Right Grant
- 2006-12-07 AU AU2006323745A patent/AU2006323745B2/en not_active Ceased
- 2006-12-07 EP EP06834239A patent/EP1970445B1/en active Active
- 2006-12-07 JP JP2007549184A patent/JP5146957B2/ja active Active
- 2006-12-07 CN CN2006800525963A patent/CN101365791B/zh not_active Expired - Fee Related
- 2006-12-07 CA CA002642657A patent/CA2642657A1/en not_active Abandoned
- 2006-12-07 US US12/096,517 patent/US8030478B2/en active Active
-
2009
- 2009-02-16 HK HK09101422.7A patent/HK1121491A1/xx unknown
Non-Patent Citations (9)
Title |
---|
HIARO I. ET AL.: "Idenshi ni Aratana Moji o Kumikomu -Jinkoteki na Sosuisei Enkitai no Kaihatsu-", BIONICS, vol. 3, no. 12, 1 December 2006 (2006-12-01), pages 68 - 71, XP003014228 * |
HIRAO I. ET AL.: "An unnatural hydrophobic base pair system: site-specific inCorp. of nucleotide analogs into DNA and RNA", NAT. METHODS, vol. 3, no. 9, September 2006 (2006-09-01), pages 729 - 735, XP003014227 * |
HIRAO I. ET AL.: "III Shinki Idenshi to Tanpakushitsu o Sosei suru Shinki Idenshi no Jinko Sosei", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 48, no. 11, 2003, pages 1496 - 1502, XP003014225 * |
HIRAO I. ET AL.: "Non-hydrogen-bonded base pairs for specific transcription", NUCLEIC ACIDS SYMP. SER., no. 49, September 2005 (2005-09-01), pages 33 - 34, XP003008209 * |
HIRAO I.: "Seimei o Tsukuru Ichi Seimei System no Rikai ni Nozomu Kagaku Idenshi Joho no Kakucho o Mezashita Jinko Enki Tai no Sekkei Kaihatsu", CHEMISTRY & CHEMICAL INDUSTRY, vol. 59, no. 8, 1 August 2006 (2006-08-01), pages 848 - 851, XP003014229 * |
LECONTE A.M. ET AL.: "Amplify this! DNA and RNA get a third base pair", NAT. METHODS, vol. 3, no. 9, September 2006 (2006-09-01), pages 667 - 668, XP003014226 * |
MITSUI T. ET AL.: "An unnatural hydrophobic base pair with shape complementarity between pyrrole-2-carbaldehyde and 9-methylimidazo(4,5)-pyridine", J. AM. CHEM. SOC., vol. 125, no. 18, 2003, pages 5298 - 5307, XP003008207 * |
See also references of EP1970445A4 * |
STUMBER M. ET AL.: "Synthesis, characterization and application of two nucleoside triphosphate analogues, GTPgammaNH2 and GTPgammaF", EUR. J. BIOCHEM., vol. 269, no. 13, 2002, pages 3270 - 3278, XP003014224 * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009099073A1 (ja) * | 2008-02-07 | 2009-08-13 | The University Of Tokyo | 非天然塩基を含む改変tRNA及びその用途 |
JP5679147B2 (ja) * | 2008-02-07 | 2015-03-04 | 独立行政法人理化学研究所 | 非天然塩基を含む改変tRNA及びその用途 |
EP2246428A1 (en) * | 2008-02-07 | 2010-11-03 | The University of Tokyo | Modified trna containing non-natural nucleotide and use thereof |
US8715984B2 (en) | 2008-02-07 | 2014-05-06 | Riken | Modified tRNA containing unnatural base and use thereof |
EP2246428A4 (en) * | 2008-02-07 | 2011-04-13 | Univ Tokyo | MODIFIED TRNA WITH NON-NATURAL NUCLEOTIDE AND USE THEREOF |
CN101981186A (zh) * | 2008-03-31 | 2011-02-23 | 塔古西库斯生物株式会社 | 可高选择性且高效率地进行pcr扩增的新型dna |
US8426569B2 (en) | 2008-03-31 | 2013-04-23 | Riken | DNA capable of being amplified by PCR with high selectivity and high efficiency |
JP5424414B2 (ja) * | 2008-03-31 | 2014-02-26 | 独立行政法人理化学研究所 | 高選択・高効率でpcr増幅が可能な新規dna |
KR101556426B1 (ko) * | 2008-03-31 | 2015-10-02 | 탁시스 바이오 가부시키가이샤 | 고선택ㆍ고효율로 pcr 증폭이 가능한 신규 dna |
AU2009232716B2 (en) * | 2008-03-31 | 2015-02-05 | Tagcyx Biotechnologies | Novel DNA capable of being amplified by PCR with high selectivity and high efficiency |
WO2009123216A1 (ja) | 2008-03-31 | 2009-10-08 | 独立行政法人理化学研究所 | 高選択・高効率でpcr増幅が可能な新規dna |
CN102741266A (zh) * | 2009-10-06 | 2012-10-17 | 塔古西库斯生物株式会社 | 形成特异碱基对的人工碱基对 |
JPWO2011043385A1 (ja) * | 2009-10-06 | 2013-03-04 | 独立行政法人理化学研究所 | 特異な塩基対を形成する人工塩基対 |
WO2011043385A1 (ja) | 2009-10-06 | 2011-04-14 | 独立行政法人理化学研究所 | 特異な塩基対を形成する人工塩基対 |
US8895712B2 (en) | 2009-10-06 | 2014-11-25 | Riken | Artificial base pair capable of forming specific base pair |
US9873879B2 (en) | 2011-11-18 | 2018-01-23 | Tagcyx Biotechnologies | Nucleic acid fragment binding to target protein |
US9540650B2 (en) | 2011-11-18 | 2017-01-10 | Tagcyx Biotechnologies | Nucleic acid fragment binding to target protein |
WO2013073602A1 (ja) * | 2011-11-18 | 2013-05-23 | 独立行政法人理化学研究所 | 標的タンパク質に結合する核酸断片 |
JPWO2013073602A1 (ja) * | 2011-11-18 | 2015-04-02 | 独立行政法人理化学研究所 | 標的タンパク質に結合する核酸断片 |
US10626138B2 (en) | 2013-08-08 | 2020-04-21 | The Scripps Research Institute National Institutes Of Health (Nih), U.S. Dept Of Health And Human Services (Dhhs) | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
US11634451B2 (en) | 2013-08-08 | 2023-04-25 | The Scripps Research Institute | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
US10513706B2 (en) | 2014-04-09 | 2019-12-24 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
US11466279B2 (en) | 2014-04-09 | 2022-10-11 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
US11761007B2 (en) | 2015-12-18 | 2023-09-19 | The Scripps Research Institute | Production of unnatural nucleotides using a CRISPR/Cas9 system |
US10696720B2 (en) | 2016-06-24 | 2020-06-30 | The Scripps Research Institute | Nucleoside triphosphate transporter and uses thereof |
US10696719B2 (en) | 2016-06-24 | 2020-06-30 | The Scripps Research Institute | Nucleoside triphosphate transporter and uses thereof |
US11834479B2 (en) | 2016-06-24 | 2023-12-05 | The Scripps Research Institute | Nucleoside triphosphate transporter and uses thereof |
US11834689B2 (en) | 2017-07-11 | 2023-12-05 | The Scripps Research Institute | Incorporation of unnatural nucleotides and methods thereof |
US11622993B2 (en) | 2017-08-03 | 2023-04-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of autoimmune diseases |
US11701407B2 (en) | 2017-08-03 | 2023-07-18 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
US10610571B2 (en) | 2017-08-03 | 2020-04-07 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
US11919934B2 (en) | 2018-02-26 | 2024-03-05 | Synthorx, Inc. | IL-15 conjugates and uses thereof |
JP7342017B2 (ja) | 2018-03-21 | 2023-09-11 | エフ. ホフマン-ラ ロシュ アーゲー | 高熱安定性を持つ修飾ヌクレオシドホスフェート |
JP2021518127A (ja) * | 2018-03-21 | 2021-08-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 高熱安定性を持つ修飾ヌクレオシドホスフェート |
US11077195B2 (en) | 2019-02-06 | 2021-08-03 | Synthorx, Inc. | IL-2 conjugates and methods of use thereof |
US11879145B2 (en) | 2019-06-14 | 2024-01-23 | The Scripps Research Institute | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms |
WO2022131350A1 (ja) * | 2020-12-18 | 2022-06-23 | タグシクス・バイオ株式会社 | Dnaアプタマーのスクリーニングに使用可能な新規人工塩基を有するデオキシリボヌクレオシド、デオキシリボヌクレオチド、およびこれを含有する核酸 |
Also Published As
Publication number | Publication date |
---|---|
US20100036111A1 (en) | 2010-02-11 |
EP1970445B1 (en) | 2012-09-26 |
CN101365791A (zh) | 2009-02-11 |
JPWO2007066737A1 (ja) | 2009-05-21 |
JP5146957B2 (ja) | 2013-02-20 |
CA2642657A1 (en) | 2007-06-14 |
HK1121491A1 (en) | 2009-04-24 |
CN101365791B (zh) | 2012-07-25 |
KR101404374B1 (ko) | 2014-06-09 |
KR20080093986A (ko) | 2008-10-22 |
AU2006323745B2 (en) | 2012-11-22 |
EP1970445A4 (en) | 2009-07-29 |
EP1970445A1 (en) | 2008-09-17 |
US8030478B2 (en) | 2011-10-04 |
AU2006323745A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007066737A1 (ja) | 核酸の複製の方法及び新規人工塩基対 | |
Xue et al. | A vitamin-C-derived DNA modification catalysed by an algal TET homologue | |
ES2827227T3 (es) | Métodos y sondas para identificar alelos génicos | |
JP2013528372A (ja) | エンドリボヌクレアーゼ組成物およびその使用方法 | |
JP2011512871A5 (ja) | ||
CN107760686B (zh) | Dkk-1蛋白的核酸适配体及其应用 | |
CN113593636B (zh) | 测序结果分析方法、系统及计算机可读存储介质和电子设备 | |
WO2019114675A1 (zh) | 一种核酸适体及其在识别并结合cd171中的应用 | |
Gao et al. | Progress in the isolation of aptamers to light-up the dyes and the applications | |
Yin et al. | Ginseng omics for ginsenoside biosynthesis | |
CN107064515A (zh) | 一种基于点击化学的铜离子检测方法及检测试剂盒 | |
CN109799350B (zh) | 蛋白热稳定测量结合双向稳定同位素标记蛋白组学筛选药物靶标的方法及应用 | |
Wen et al. | Transcriptomic and proteomic analyses reveal the common and unique pathway (s) underlying different skin colors of leopard coral grouper (Plectropomus leopardus) | |
CN108289924A (zh) | 阻断组蛋白识别结构域的小分子 | |
WO2016119448A2 (zh) | 不同种属微生物间种类和丰度比较的人工外源性参照分子 | |
WO2023202030A1 (zh) | 一种小分子rna的高通量测序文库构建方法 | |
Duan et al. | Proteome evaluation of homolog abundance patterns in Arachis hypogaea cv. Tifrunner | |
CN114621958B (zh) | 特异性识别atp的单链dna适配体序列及其应用 | |
US20230041228A1 (en) | Small Molecule Inhibition of Micro-RNA-210 Reprograms an Oncogenic Hypoxic Circuit | |
US20220267839A1 (en) | Target validation, binding site identification, and profiling of rna targets | |
US20140024540A1 (en) | Ligand identification | |
KR101392970B1 (ko) | 민감도와 특이도가 향상된 표적 핵산의 검출방법 | |
Hirose et al. | A Case Study on the Keap1 Interaction with Peptide Sequence Epitopes Selected by the Peptidomic mRNA Display | |
CN109439655A (zh) | 适用于超微量细胞核酸提取的试剂盒及方法 | |
Merritt et al. | Parallel analysis of mutant human glucose 6‐phosphate dehydrogenase in yeast using PCR colonies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007549184 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087016493 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006323745 Country of ref document: AU Ref document number: 3527/CHENP/2008 Country of ref document: IN Ref document number: 2006834239 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006323745 Country of ref document: AU Date of ref document: 20061207 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680052596.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2642657 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12096517 Country of ref document: US |